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Piperlongumine is a natural amide alkaloid isolated from several species of Piper and is 
described in the literature as selectively cytotoxic to several cancer cell lines. Inhibiting cell 
migration has gained considerable interest as an approach for discovering antimetastatic agents 
because this process is fundamental to metastasis. Piperlongumine, selected from cell-based assay 
screening of NuBBE Database, inhibited the migration of MDA-MB-231 breast cancer cells with 
an EC50 of 3.0 ± 1.0 µM by the Boyden chamber assay. A series of five analogous compounds based 
on the structure of piperlongumine were designed, synthesized and evaluated in cell migration 
and cytotoxicity assays. The analogue designed by molecular simplification ((E)-N-acryloyl-3-
(3,4,5-trimethoxyphenyl)acrylamide) was the most active of the series, with an EC50 of 1.5 ± 1 µM. 
Additionally, this compound was selectively cytotoxic, with a selectivity index (SI) of 4.4.
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Introduction
Metastasis is the process by which undifferentiated 
cancer cells migrate to other parts of the body.1,2 Suppression 
of metastasis is an urgent need in cancer treatment, as most 
existing drugs only inhibit cell proliferation.3 Traditionally, 
chemotherapy is based on cytotoxic therapeutic agents 
that inhibit proliferation and cause cell death. However, 
the strategy of inhibiting cell migration has recently 
gained considerable interest.4 Several compounds that 
inhibit the process of metastasis have been described to 
date.5,6 Paclitaxel, which was originally discovered as an 
antimitotic agent that disrupts the cell cycle in cancer cells 
by stabilizing microtubules, exhibits marked and selective 
inhibition of tumor cell migration.7
As extensively reviewed elsewhere, biodiversity in 
nature has provided unique chemical scaffolds that have 
been used as templates for medicinal chemistry and drug 
discovery.8-13 The availability of natural compound libraries 
is of significant importance for integrating natural products 
and medicinal chemistry, especially for the identification of 
new bioactive agents and the rational design of compounds 
in drug discovery.14 Within this context, we selected 
the natural product piperlongumine (1), also known as 
piplartine, from cell-based assay screening of NuBBE 
Database (NuBBEDB)15 and evaluated its ability to inhibit 
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cancer cell migration using biological and target-based 
experiments.
Piperlongumine (1, Figure 1) is an alkamide isolated 
from several species of Piper (Piperaceae).16 It is described 
as possessing antifungal properties,17 cytotoxicity toward 
several cancer cell lines,18,19 and trypanocidal effects,20 
as well as other biological activities.21 Furthermore, 
piperlongumine selectively induces cell death in cancer 
cells but does not reduce viability in normal cells.22 
This natural compound also demonstrates an interesting 
capacity to reduce angiogenesis and inhibit the formation 
of blood vessels in tumor xenografts in mice.22,23 Recent 
work suggests that piperlongumine is more effective than 
paclitaxel in inhibiting tumor growth and presents excellent 
oral bioavailability.22 Piperlongumine causes an increase 
in reactive oxygen species (ROS) levels in cancer cells 
but not in normal cells,22 and piperlongumine analogues 
also enhanced ROS in PC-3 cells.24 This activity may be 
at least partly due to proteasome inhibition and may be 
responsible for the selective activity of piperlongumine.25,26 
Nonetheless, few studies to date have investigated the 
impact of this compound on cell migration.27 Accordingly, 
we describe an analysis of piperlongumine as an inhibitor 
of the migration of breast cancer cell line MDA-MB-231 
and an evaluation of its cytotoxicity toward normal and 
cancer cell lines. Additionally, we aimed at improving 
the biological activity of this compound through the 
design, synthesis and biological evaluation of a series of 
its derivatives.
Results and Discussion
The study of cell migration and its underlying 
mechanisms is of great significance in various fields, 
including cancer drug development. Tumor cell migration 
is one of the processes necessary for metastasis, and several 
approaches have been used to assess the ability of cells to 
cross tissue barriers.28 In this work, in vitro cell assays of 
a wound-healing29 and Boyden chamber30 method were 
performed to evaluate the ability of piperlongumine and its 
analogues (2-6) to inhibit the migration of MDA-MB-231 
cancer cells. Those compounds with clearly observable 
activities were further subjected to cytotoxicity assays using 
the cancer cell lines MDA-MB-231 and DU-145, as well as 
the normal breast cell line (MCF10A), to further evaluate 
their toxicity toward and selectivity for malignant cells.31
Evaluation of piperlongumine activity as an inhibitor of 
tumor cell migration
Wound-healing cell assay
The wound-healing assay is a simple and effective 
in vitro method employed to qualitatively evaluate the 
influence of compounds on cell migration. Wounds are 
typically created by the removal of a portion of confluent 
cells growing in a multiwell plate using a pipette tip; closure 
of the uncovered area can then be observed and measured 
over time using microscopy or a computer imaging 
system.29 Positive activity is identified by measuring the 
area of the unclosed wound that remains. Piperlongumine 
at 10 µM inhibited 97% of cell migration (Table 1). At 
this concentration, its activity was similar to the positive 
control colchicine, which inhibited 72% of cell migration 
at 1 µM (Table 1).
Boyden chamber cell assay
Invasion of basement membranes by tumor cells and 
the cells’ migration to distant tissues are crucial steps in the 
complex multistage process that leads to the formation of a 
metastasis. Tumor cells cross basement membranes, invade 
the lymphatic or vascular system during dissemination and 
then penetrate into a target tissue. The Boyden chamber 
assay employs a two-compartment system separated 
by a membrane to quantitatively evaluate the effect of 
compounds on the migration of cancer cells in vitro.28,30
Piperlongumine exhibited an EC50 of 3.0 ± 1.0 µM 
by the Boyden chamber assay, which is comparable to 
that of colchicine, 0.5 ± 0.1 µM, as shown in Table 1. 
These results indicate that piperlongumine possesses the 
ability to inhibit cell migration with similar potency as 
the positive control colchicine (Table 1). Furthermore, 
these results are in agreement with those obtained from 
wound-healing assays.
Figure 1. Piperlongumine, a natural amide isolated from several species 
of Piper (Piperaceae).
Table 1. Effects of piperlongumine and colchicine on MDA-MB-231 





Boyden chamberb EC50 
/ µM
Colchicine 70 (1 µM) 0.5 ± 0.1
Piperlongumine 97 (10 µM) 3.0 ± 1.0
aAverage of three independent experiments; baverage of two independent 
experiments.
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Design and synthesis of compounds using the natural 
product piperlongumine as a scaffold
A series of synthesized piperlongumine analogues 
was recently reported, and it was proposed that the two 
reactive electrophilic sites are essential for the toxicity 
of these compounds.32 To enhance the compound’s cell 
migration-inhibiting activity, a series of analogues were 
designed by taking into account information in the literature 
and concepts of molecular simplification and hybridization. 
Because the reported substitutions on the aromatic ring of the 
3,4,5-trimethoxy cinnamic moiety do not affect the antitumor 
activity of the compound, we did not modify this part of the 
molecule.22,32 Additionally, considering that the double bond 
at C12−C13 is a key pharmacophore and that the double 
bond at C7−C8 plays a significant role in cell toxicity,32 we 
planned modifications of the d-valerolactam ring to study the 
effect of this scaffold on cell migration (2-4). Furthermore, 
we designed one compound using molecular simplification 
by retaining the Michael acceptor and the double bond at 
C12−C13, but by removing the lactam (piperidonic) ring (5). 
Finally, we used molecular hybridization to design a 
hybrid of piperlongumine and chromene (6), the latter of 
which is widely known for its cytotoxicity and induction 
of apoptosis.33 The designed compounds are presented in 
Scheme 1.
The synthesis of piperlongumine using different 
methods is described in the literature.32,34-37 One of the 
newest and simplest approaches for amide bond formation 
consists of the coupling of the NH-lactam (piperidonic 
group) with 3,4,5-trimethoxy cinnamoyl chloride in the 
presence of a base.32 Accordingly, the designed compounds 
were synthesized in this way from the corresponding 
commercially available nitrogen-bearing reagents, as 
described in Scheme 2.32 The conditions that were able 
to enhance the nucleophilicity of the nitrogenous reagent, 
including the nature of the solvent, were dependent on 
the reactivity of this reagent. A detailed description of the 
synthetic methods together with their characterization is 
presented in Synthetic methods sub-section.
Biological evaluation of the synthesized compounds
All the synthesized compounds were evaluated by both 
the wound-healing and Boyden chamber assays as well as 
for their cytotoxicity toward MDA-MB-231, DU-145 and 
MCF10A cell lines. The results obtained are presented in 
Tables 2 to 4.
Scheme 1. Piperlongumine (1) as the natural product model for compound design.
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The analogue designed by molecular simplification (5) 
was highly active, inhibiting 97% of MDA-MB-231 cell 
migration at 10 µM. Compound 4 presented moderate 
activity, with only 50% inhibition of cell migration at 
10 µM. The other synthesized compounds presented no 
activity at the concentration range evaluated in this assay. 
The most promising designed compound (5) maintains the 
biological activity of piperlongumine while possessing a 
simpler structure.
According to the Boyden chamber assay, compound 5 
has an EC50 of 1.5 ± 1.0 µM, which is comparable to the 
EC50 of colchicine (0.5 ± 0.1 µM), as presented in Table 3. 
Interestingly, compound 5 displays increased inhibition 
capacity compared to the original parent compound 
piperlongumine.
Piperlongumine and 5 display selective toxicity toward 
the normal breast cell line MCF10A. Compound 5 inhibits the 
growth of MDA-MB-231 cells with an EC50 of 9.0 ± 1.0 µM 
and that of normal MCF10A cells with an EC50 of 40 ± 5 µM. 
The degree of selectivity can be expressed as the selectivity 
index (SI = EC50 for the normal breast cell line MCF10A / EC50 
for the cancer cell line MDA-MB-231), which is 4.4 for 
compound 5. Piperlongumine has a similar effect, with 
an EC50 of 7.0 ± 1.0 µM against MDA-MB-231 breast 
cancer cells and an EC50 of 38 ± 8 µM against MCF10A 
normal breast cells, corresponding to an SI of 5.4 (Table 4). 
The cytotoxicity evaluation shows that compound 5 and 
piperlongumine have greater cytotoxic effects (EC50 values) 
compared to effects on cell migration, suggesting that their 
inhibition of cell migration may not be due to their toxicity.
Tubulin polymerization assay
Microtubules are essential for the development and 
maintenance of cell shape, division and mitosis and 
are also involved in cell signalling and the transport of 
vesicles, mitochondria and other components inside 
cells.38-44 Microtubules are formed via a dynamic 
process of polymerization and depolymerization of 
Scheme 2. Synthesis of piperlongumine analogues 2-6. Reagents and conditions: (a) (COCl)2, DMF (cat.), CH2Cl2, r.t., 2 h; (b) described in Synthetic 
methods sub-section.
Table 2. Effects of piperlongumine analogues (2-6) on the results of 
wound-healing (MDA-MB-231 cells) assays








aEvaluated at 1 µM.
Table 3. Effects of 5 and colchicine on MDA-MB-231 breast cancer 
cell migration
Compound
Wound healinga / 
(% inhibition at 10 µM)
Boyden chamberb 
EC50 / µM
Colchicine 70 0.5 ± 0.1
5 97 1.5 ± 1.0
aAverage of three independent experiments; baverage of two independent 
experiments.
Table 4. Cytotoxicities of piperlongumine and 5 against MDA-MB-231, DU-145 and MCF10A cell lines
Compound EC50 MDA-MB-231 / µM EC50 DU-145 / µM EC50 MCF10A / µM Selectivity index (SI)
Doxorubicin 3.0 ± 1.0 5.5 ± 0.5 30 ± 8 10
Piperlongumine 7.0 ± 1.0 11.0 ± 3.0 38 ± 8 5.4
5 9.0 ± 1.0 12.0 ± 1.0 40 ± 5 4.4
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heterodimers formed by α- and β-tubulin proteins.42,44,45 
Due to their essential role during cellular division processes, 
microtubules are among the most common and effective 
targets in cancer cells.
Recent studies have reported the ability of aryl-
substituted piperlongumine analogues to inhibit microtubule 
polymerization in vitro.46 However, other independent 
studies of piperlongumine and similar derivatives have 
demonstrated substantial anti-inflammatory activity for 
this class of compounds. Based on these facts and the 
interesting potential of microtubules as an anticancer 
target, we performed fluorescence-based in vitro studies 
to evaluate the ability of piperlongumine to inhibit 
microtubule formation and to characterize this system as 
a possible molecular mechanism explaining the activity of 
this molecule and its derivatives.
The evaluation of microtubule polymerization in the 
presence of different concentrations of piperlongumine is 
shown in Figure 2.
Although colchicine completely inhibited microtubule 
formation at a concentration of 10 µM, piperlongumine did 
not affect the formation of microtubules in vitro over a range 
of 1 to 200 µM. These results indicate that piperlongumine 
does not interact with tubulin and is unable to modulate 
microtubule polymerization. Accordingly, the findings 
suggest a different mechanism underlying the anticancer 
activity of piperlongumine and its derivatives, which may 
be related to anti-inflammatory effects.47,48
Conclusions
This work represents an interesting example of the 
significant structural variability in natural products 
and the usefulness of this variability in drug discovery. 
Piperlongumine, which was selected among many 
natural compounds already identified and available in 
NuBBEDB, inhibited migration of the breast cancer cell line 
MDA-MB-231 with an EC50 of 3 ± 1 µM by the Boyden 
chamber assay. Additionally, we designed and synthesized 
five analogues of piperlongumine through molecular 
simplification. Among these compounds, 5 was the most 
active, with an EC50 of 1.5 ± 1 µM against breast cancer 
cell MDA-MB-231 migration by the Boyden chamber 
assay. Additionally, we evaluated the cytotoxicity of these 
compounds, and both piperlongumine and 5 presented 
high selectivity for tumor cells, with a selectivity index 
of 4.44 and 5.42, respectively. Furthermore, taking into 
account the reported activities of piperlongumine as an anti-
inflammatory agent and inhibitor of microtubule activity, 
we evaluated the ability of this compound to modulate 
tubulin polymerization in vitro. The results suggest that 
piperlongumine does not interact with microtubules and 
that its activity is likely related to another molecular 
mechanism.
Experimental
Isolation of piperlongumine (1)
The fruits of Piper tuberculatum were harvested from 
a specimen growing under greenhouse conditions at the 
Institute of Chemistry (UNESP, Araraquara, São Paulo 
State, Brazil) in January of 2012. The botanical material 
was properly identified by Dr Guillermo E. D. Paredes 
from the University Pedro Ruiz Gallo in Peru. A voucher 
specimen (K-167) was deposited in the herbarium of the 
Institute of Botany of São Paulo in São Paulo, Brazil. The 
dried fruits (803 g) were extracted by maceration with 
dichloromethane:methanol (2:1, 3 × 1200 mL) under 
ultrasonication. The residue was concentrated under 
vacuum to obtain 48.90 g of extract (6.1%). The whole 
extract was first fractioned under low pressure by normal-
phase column chromatography with silica gel (70 mesh) as 
the stationary phase (63 µM, 300 × 60 mm). The solvent 
system was a mixture of (A) n-hexane and (B) ethyl 
acetate in a gradient from 5 to 50% B, which afforded 
11 fractions. Fraction 3 formed a precipitate, which was 
filtered and washed with MeOH in an ice bath to furnish 
piperlongumine (1, 1.19 g). 1H NMR (600 MHz, CDCl3) 
d (ppm) 2.43 (2H, m, J 6.3, 4.3, 1.8 Hz), 3.82 (3H, s), 3.84 
(6H, s), 3.99 (2H, t, J 6.5 Hz), 5.99 (1H, dt, J 9.7, 1.7 Hz), 
6.75 (2H, s), 6.89 (1H, dt, J 9.4, 4.1 Hz), 7.37 (1H, d, 
J 15.5 Hz), 7.62 (1H, d, J 15.5 Hz).
Figure 2. Fluorescence-based microtubule polymerization assays in 
the presence of different concentrations of piperlongumine (from 1 to 
200 µM). DMSO and colchicine at 10 µM were used as negative and 
positive controls, respectively, for polymerization inhibition. The data 
correspond to the average value of three independent replicates.
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Cell assays
Cell cultures
MDA-MB-231 human breast cancer cells were cultured 
at 37 °C and 5% CO2 in Leibovitz’s medium, and MCF-7 
human breast cancer cells were cultured in DMEM 
(Dulbecco’s modified Eagle’s medium, Cultilab) at 37 °C 
and 5% CO2. DU-145 human prostate tumor cells were 
cultured under the same conditions using RPMI (Roswell 
Park Memorial Institute medium). The cells were stored in 
liquid nitrogen in culture medium containing 5% DMSO 
and 20% foetal bovine serum (FBS, sterile, Cultilab).
Wound-healing assay
A wound-healing assay was performed to qualitatively 
assess the potential of the compounds to inhibit cell 
migration.29 Cells were cultured in 24-well plates (1 × 105 cells 
per well) containing 1 mL of culture medium and 10% FBS. 
After the cells reached confluence, the culture medium was 
removed, and a wound was generated in the cell monolayer 
with the aid of a sterile pipette tip. The test compounds 
were dissolved in DMSO, diluted in the culture medium 
and added to each well (final DMSO concentration = 0.1%). 
The system was photographed using a Nikon Eclipse TS100 
inverted microscope (4× magnification, Nikon Instruments 
Inc., Melville, NY, USA); images were taken at 0 h and 
after 22 h of incubation at 37 °C and 5% CO2. The percent 
inhibition shown by the test compound was determined by 
the difference in the wound area at 0 and 22 h. The extent 
of the area was measured using NIS - Elements software. 
The assays were performed in triplicate, with colchicine as 
a positive control and DMSO as a negative control.29
Boyden chamber assay
The Boyden chamber assay was performed to 
quantitatively evaluate the effect of the compounds on cell 
migration.28,30 This assay utilizes a hollow plastic chamber 
that is sealed at one end with a porous membrane. This 
chamber/insert is suspended over a larger well that contains 
medium and a chemoattractant. Cells are placed inside the 
insert and allowed to migrate through the pores from one 
side of the membrane to the other. Migratory cells are then 
stained and counted. The assays were performed in 24-well 
plates (BD BioCoatTM Migration/Invasion Chambers) with 
inserts of 6.5 mm diameter and 8 µM pore size. To the inner 
part of the insert (upper chamber), 4 × 104 cells/300 µL 
culture medium (without FBS) and the test compound were 
added; to the lower compartment (well of the plate), 700 µL 
of culture medium supplemented with 10% FBS and the 
test compound were added. This system was incubated for 
6 h at 37 °C and 5% CO2. After incubation, the medium 
in the insert was removed along with the cells that had not 
migrated to the bottom of the membrane. The cells that 
had migrated to the lower portion of the membrane were 
fixed and stained with 1% aqueous toluidine blue in borax 
for 5 min. The membranes were cut using a surgical lancet 
and placed on a slide, and the migrated cells were counted 
using a Nikon Eclipse E600 optical microscope (Nikon 
Instruments Inc., Melville, NY, USA) and NIS-Elements 
Image processing software. The assays were performed in 
duplicate using colchicine as a positive control and DMSO 
as a negative control. The EC50 was determined from the 
curve of the log concentration versus the percent inhibition. 
The curves were plotted using data obtained for six different 
concentrations of the compounds tested in duplicate. The 
curves were fitted using the software Sigmaplot 11.0 by the 
method of nonlinear regression - dynamic fitting.
Cytotoxicity assay
A cytotoxicity evaluation was performed to test the 
toxicity of the compounds toward the cancer cell lines 
MDA-MB- 231 and DU-145. The assay was performed 
in 96-well plates to which approximately 5 × 103 cells 
per well were added. After checking cell adhesion (at 
approximately 24 hours), piplartine was dissolved in 
DMSO in a concentration of 100 mM (stock solution). 
For the assay, compounds were added into wells in serial 
dilutions (100-0.04 µM). The plate was incubated for 24 h, 
after which 20 µL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) was added to each well. After 4 h of incubation, the 
absorbance was measured at 490 nm using a SpectraMax Plus 
384 - Absorbance Microplate Reader (Molecular Devices, 
Sunnyvale, USA). The plate was maintained at 24 °C, and 
the assays were performed in triplicate using doxorubicin 
as a positive control and DMSO as a negative control.31
Tubulin polymerization assay (fluorescence based)
A fluorescence-based assay was applied (Cytoskeleton 
Inc., Denver, CO, USA) to determine the EC50 of effects 
on tubulin polymerization.49-52
Microtubule-associated, protein-rich tubulin protein 
(2 mg mL-1, porcine, cytoskeleton) in a buffer containing 
80 mM piperazine-N,N’-bis[2-ethanesulfonic acid] 
sequisodium salt (PIPES) at pH 6.9, 2.0 mM magnesium 
chloride, 0.5 mM ethylene glycol-bis(β-amino-ethyl ether) 
N,N,N’,N’-tetra-acetic acid (EGTA), 1.0 mM guanosine 
triphosphate (GTP) and 10% glycerol was placed in 
each well of a 96-well plate (OptiPlate F -1536 - Black; 
PerkinElmer Inc., Waltham, MA, USA). For each assay, 
45 µL of the tubulin solution was incubated with 5 µL of 
the compound at a 10-fold concentration and 10% dimethyl 
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sulfoxide (DMSO), resulting in a final solution with the 
desired concentration of 1% DMSO.49 All assays were 
performed in triplicate, with 1% DMSO as the negative 
control and 10 µM colchicine as the positive control. 
Using an excitation wavelength of 360 nm, the rate of 
polymerization was monitored at 37 °C by measuring the 
fluorescence emission at 440 nm with a Victor 3 fluorimeter 
plate reader and Wallac 1420 Multilabel Plate Counter 
software (PerkinElmer Inc., Waltham, MA, USA).
Materials and instruments
Reagents were purchased from Sigma-Aldrich, 
Acros Organics, or Fluka and were used without further 
purification; solvents were purified according to standard 
methods.53 Reaction progress was monitored by thin layer 
chromatography (TLC) on aluminium plates pre-coated 
with silica gel F254 layers (0.2 mm thickness; Whatman) 
and visualized under UV light (254 and 366 nm). Column 
chromatography was carried out over silica gel (particle 
size of 35-70 µM; Acros Organics). 1H NMR spectra were 
recorded using Bruker AC 300 (300 MHz), Bruker Avance 
400 (400 MHz) or Bruker Avance III 600 (600 MHz) 
spectrometers; spectra were referenced against the internal 
standard TMS (dTMS 0.00) or against the residual solvent 
resonances of CDCl3 (d 7.26 1H); the multiplicity (s, 
singlet; d, doublet; t, triplet; q, quartet; dd, doublet of 
doublet) and coupling constant (Hz) are noted. 13C NMR 
spectra were recorded using Bruker AC 300 (75 MHz) or 
Bruker Avance III 600 (150 MHz) spectrometers. 13C NMR 
chemical shifts are reported in parts per million relative to 
the solvent. All 13C NMR spectra were determined with 
broadband decoupling. When necessary, the structures of 
the compounds were verified and the signals unambiguously 
assigned by 2D NMR techniques: 1H-1H COSY (correlation 
spectroscopy), 1H-1H NOESY (nuclear Overhauser effect 
spectroscopy), 13C-1H HMQC (heteronuclear multiple 
quantum correlation), and 13C-1H HMBC (heteronuclear 
multiple bond correlation). Some 13C values were assigned 
using evidence from HMBC and are marked with an asterisk 
in Synthetic methods sub-section. Electrospray ionization 
time-of-flight (ESI-TOF) high-resolution mass spectra 
(HRMS) were measured using a MicrOTOF Q II spectrometer 
(Bruker Daltonics, Billerica, MA, USA) operating in positive 
ion mode. ChemDraw Ultra 8.0 was used to calculate the 
values of the pseudo-molecular ions [M + H]+ and [M + Na]+.
Synthetic methods
(E)-3-(3,4,5-Trimethoxyphenyl)acryloyl chloride (7)
To a solution of (E)-3,4,5-trimethoxycinnamic acid 
(200 mg, 0.84 mmol) in CH2Cl2 (8.0 mL) under a nitrogen 
atmosphere was added oxalyl chloride (358 µL, 4.2 mmol) 
and a catalytic amount of dimethylformamide (DMF). The 
reaction was stirred at room temperature for 2 hours. The 
residue, compound 7, a yellow solid, was dried and used 
in the next step without further purification.32
1-((E)-3-(3,4,5-Trimethoxyphenyl)acryloyl)-1H-pyrrole-2,5-
dione (2)
CH2Cl2 (8 mL), triethylamine (352 µL, 2.52 mmol), and 
maleimide (96 mg, 1 mmol) were added to 7 (0.84 mmol). 
The reaction mixture was stirred at room temperature 
overnight and then quenched by addition of a saturated 
aqueous ammonium chloride solution. The product was 
extracted with CH2Cl2; the combined extracts were dried 
over MgSO4 and filtered, and the solvent was removed 
under reduced pressure.32 The product was purified by 
column chromatography using cyclohexane:ethyl acetate 
(7:3) for elution to afford compound 2 (121 mg, 45% 
yield) as a pure reddish-brown solid. 1H NMR (400 MHz, 
CDCl3) d (ppm) 3.94 (s, 3H), 3.95 (s, 6H), 6.88 (s, 
2H), 6.92 (s, 2H), 7.23 (d, 1H, J 15.5 Hz), 7.91 (d, 1H, 
J 15.5 Hz); 13C NMR (75 MHz, CDCl3) d 56.2, 61.0, 
106.0, 117.9, 129.6, 135.4, 141.0*, 148.4, 153.5, 162.5*, 
167.9; Figures S1-S3 in Supplementary Information; 
HRMS (ESI-TOF) m/z: 318.0977 [M + H]+ (calcd. for 




CH2Cl2 (8 mL), triethylamine (352 µL, 2.52 mmol), 
and phthalimide (147 mg, 1 mmol) were added to 7 
(0.84 mmol). The reaction mixture was stirred at room 
temperature overnight and then quenched by addition 
of a saturated aqueous ammonium chloride solution. 
The product was extracted with CH2Cl2; the combined 
extracts were dried over MgSO4 and filtered, and the 
solvent was removed under reduced pressure.32 The 
residue was purified by column chromatography using 
cyclohexane:ethyl acetate (7:3) for elution to afford 
compound 3 (121 mg, 40% yield) as a pure light yellow 
solid. 1H NMR (600 MHz, CDCl3) d 3.90 (s, 3H), 3.92 
(s, 6H), 6.86 (s, 2H), 7.28 (d, 1H, J 15.5 Hz), 7.86 (dd, 
2H, J 5.5, 3.0 Hz), 7.90 (d, 1H, J 15.5 Hz), 8.00 (dd, 2H, 
J 5.5, 3.0 Hz); 13C NMR (150 MHz, CDCl3) d 56.2, 61.0, 
106.0, 118.7, 124.4, 129.7, 131.4, 135.4, 141.0, 147.9, 
153.5, 163.7, 165.7; Figures S4-S6 in Supplementary 
Information; HRMS (ESI-TOF) m/z: 368.1132 [M + H]+ 
(calcd. for C20H18NO6, 368.1129), 390.0948 [M + Na]+ 
(calcd. for C20H17NNaO6, 390.0948).
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(E)-1-(1H-Indol-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-
1-one (4)
CH2Cl2 (4 mL), sodium hydride (33 mg, 0.84 mmol), 
and indole (59 mg, 0.5 mmol) were added to 7 (0.42 mmol). 
The reaction mixture was stirred at room temperature 
overnight and then quenched by addition of a saturated 
aqueous ammonium chloride solution. The product was 
extracted with CH2Cl2; the combined extracts were dried 
over MgSO4 and filtered, and the solvent was removed 
under reduced pressure.32 The residue was purified by 
column chromatography using cyclohexane:ethyl acetate 
(7:3) for elution to afford compound 4 (58 mg, 41% 
yield) as a pure reddish-brown solid. 1H NMR (400 MHz, 
CDCl3) d 3.96 (s, 3H), 3.99 (s, 6H), 6.74 (d, 1H, J 3.7 Hz), 
6.89 (s, 2H), 7.16 (d, 1H, J 15.3 Hz), 7.32 (dd, 1H, J 8.0, 
7.8 Hz), 7.41 (dd, 1H, J 8.2, 8.0 Hz), 7.63 (d, 1H, J 7.8 Hz), 
7.69 (d, 1H, J 3.7 Hz), 7.94 (d, 1H, J 15.3 Hz), 8.57 (d, 
1H, J 8.2 Hz); 13C NMR (75 MHz, CDCl3) d 56.3, 61.0, 
105.6, 109.2, 116.4, 116.9, 120.9, 123.8, 124.6, 125.1, 
129.9*, 130.5*, 135.8*, 140.5*, 146.7, 153.5, 164.2*; 
Figures S7-S9 in Supplementary Information; HRMS 
(ESI-TOF) m/z: 338.1386 [M + H]+ (calcd. for C20H20NO4, 
338.1387), 360.1219 [M + Na]+ (calcd. for C20H19NNaO4, 
360.1206).
(E)-N-Acryloyl-3-(3,4,5-trimethoxyphenyl)acrylamide (5)
To a solution of acrylamide (710 mg, 10 mmol) in THF 
(50 mL) at −78 °C, n-BuLi (4.8 mL, 12 mmol; 2.5 M in 
n-hexane) was added dropwise. The reaction mixture was 
warmed to room temperature, and the reaction proceeded 
for 7 hours. The reaction mixture was cooled to −78 °C, 
and a solution of 7 (20 mmol) in THF (28 mL) was added 
dropwise. The reaction was warmed to room temperature, 
allowed to proceed for 15 hours and then quenched by 
addition of a saturated aqueous ammonium chloride 
solution. The reaction mixture was extracted with diethyl 
ether; the combined organic extracts were washed with a 
saturated solution of sodium chloride, dried over MgSO4, 
filtered and evaporated to dryness under vacuum. The 
residue was purified by successive recrystallization from 
ethyl ether (30 mL) and subsequently with ethanol (70 mL) 
to afford compound 5 (920 mg, 30% yield) as a pure yellow 
solid.37 1H NMR (600 MHz, CDCl3) d 3.89 (s, 3H), 3.90 (s, 
6H), 5.94 (dd, 1H, J 10.5, 1.2 Hz), 6.56 (dd, 1H, J, 16.6, 
1.2 Hz), 6.77 (dd, 1H, J 16.6, 10.5 Hz), 6.83 (s, 2H), 7.31 
(d, 1H, J 15.6 Hz), 7.79 (d, 1H, J 15.6 Hz), 9.17 (s, 1H); 
13C NMR (150 MHz, CDCl3) d 56.2, 61.0, 105.8, 118.6, 
129.8, 130.3, 131.2, 140.6, 146.5, 153.4, 165.6, 166.9; 
Figures S10-S12 in Supplementary Information; HRMS 
(ESI-TOF) m/z: 292.1188 [M + H]+ (calcd. for C15H18NO5, 
292.1179), 314.1016 [M + Na]+ (calcd. for C15H17NNaO5, 
314.0999). The synthesis of this compound by a similar 
method was recently described.54
(2E)-3-(3,4,5-Trimethoxyphenyl)-N-(2-oxo-2H-chromen-6-
yl)acrylamide (6)
CH2Cl2 (1 mL), triethylamine (352 µL, 2.52 mmol), and 
6-amino-chromen-2-one (161 mg, 1 mmol) were added to 
7 (0.84 mmol). The reaction mixture was stirred at room 
temperature for 2 hours and then quenched by addition of a 
saturated aqueous ammonium chloride solution. The product 
was extracted with ethyl acetate; the combined extracts were 
dried over MgSO4 and filtered, and the solvent removed 
under reduced pressure.32 The residue was purified by column 
chromatography using an n-hexane:ethyl acetate gradient 
from 7:3 to 0:1 for elution to afford compound 6 (80 mg, 
21% yield) as a pure light yellow solid.32 1H NMR (600 MHz, 
CDCl3) d 3.89 (s, 3H), 3.91 (s, 6H), 6.47 (d, 1H, J 9.5 Hz), 
6.54 (d, 1H, J 15.3 Hz), 6.78 (s, 2H), 7.30 (d, 1H, J 8.9 Hz), 
7.51 (dd, 1H, J 8.9, 2.5 Hz), 7.71 (d, 1H, J 15.3 Hz), 7.73 
(d, 1H, J 9.5 Hz), 7.81 (s, 1H), 8.18 (bs, 1H; obs.: broad 
signal); 13C NMR (150 MHz, CDCl3) d 56.2, 61.0, 105.3, 
117.2, 117.3, 118.5, 119.1, 119.6, 123.5, 129.9, 134.6, 140.1, 
142.9, 143.5, 150.5, 153.5, 160.8, 164.1; Figures S13-S15 
in Supplementary Information; HRMS (ESI-TOF) 
m/z: 382.1285 [M + H]+ (calcd. for C21H20NO6, 382.1285), 
404.1097 [M + Na]+ (calcd. for C21H19NNaO6, 404.1105).
Supplementary Information
Supplementary information (NMR spectra) is available 
free of charge at http://jbcs.sbq.org.br as PDF file.
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